GlassScriptPhysician profile
Anis Hanna
NPI 1639136245
$10,190.24
in general payments reported to CMS, 2019-2025
37 companies · $2,838 in 2025
The $2,838 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $289 · 2021: $204 · 2022: $1,249 · 2023: $2,564 · 2024: $2,375 · 2025: $2,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,711 · Education: $66.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,710.66 |
| Education | $66.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,936.55 | 2019-2025 | |
| Janssen Biotech, INC. | $1,237.91 | 2019-2025 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $949.71 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $844.37 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $553.27 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $514.15 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Madrigal Pharmaceuticals | $496.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $448.03 | 2022-2025 | |
| Ardelyx, INC. | $376.25 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $360.03 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $303.68 | 2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $250.00 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $221.52 | 2019-2024 | Dificid, Zinplava |
| Intercept Pharmaceuticals, INC. | $216.46 | 2020-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $196.34 | 2022-2025 | Dupixent |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $195.63 | 2023 | Signia, Pillcam |
| Ipsen Biopharmaceuticals, INC | $148.15 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $127.61 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $85.40 | 2019-2025 | Wegovy |
| Celltrion USA INC. | $82.44 | 2023-2024 | Yuflyma, Vegzelma |
| Ironwood Pharmaceuticals, INC | $81.12 | 2020-2024 | |
| Evoke Pharma, INC. | $77.28 | 2024-2025 | |
| Mylan Institutional INC. | $64.84 | 2023 | Hulio |
| Nestle Healthcare Nutrition INC. | $59.78 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $53.53 | 2022-2023 | Rebyota |
| Amgen INC. | $49.96 | 2019-2022 | |
| Biocon Biologics INC | $46.09 | 2025 | Yesintek |
| Gilead Sciences, INC. | $32.84 | 2022 | |
| Redhill Biopharma INC. | $29.72 | 2021-2022 | |
| Incyte Corporation | $27.81 | 2024 | Jakafi |
| Ethicon US, LLC | $23.27 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.05 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.93 | 2019 | |
| Braintree Laboratories, INC. | $18.78 | 2025 | Suflave, Sutab |
| Organon LLC | $14.32 | 2024 | |
| Shire North American Group INC | $13.61 | 2019 | |
| Allergan, INC. | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anis Hanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.